PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.43%
Revenue growth near Medical - Pharmaceuticals median of 1.43%. Charlie Munger might attribute this to overall industry trends.
-0.51%
Negative gross profit growth while Medical - Pharmaceuticals median is 1.46%. Seth Klarman would suspect poor product pricing or inefficient production.
51.44%
EBIT growth exceeding 1.5x Medical - Pharmaceuticals median of 0.45%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
1.06%
Operating income growth of 1.06% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
52.44%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 2.45%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
52.44%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 3.03%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
52.44%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 3.03%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
0.00%
Share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.21%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
0.00%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.19%. Joel Greenblatt would see a meaningful advantage if shares are undervalued.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.55%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 31.94%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
59.61%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 16.34%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
26.86%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 15.40%. Joel Greenblatt might see a short-term competitive advantage at play.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
222.32%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 27.15% over a decade. Joel Greenblatt might see a standout compounder of earnings.
177.62%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 1.67%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
107.89%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 9.82%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
194.93%
Equity/share CAGR of 194.93% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
125.91%
5Y equity/share CAGR of 125.91% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
59.94%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 1.12%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reductions while Medical - Pharmaceuticals median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
10.26%
Receivables growth far exceeding Medical - Pharmaceuticals median. Jim Chanos suspects potential red flags in revenue quality.
-1.27%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
1.24%
Asset growth exceeding 1.5x Medical - Pharmaceuticals median of 0.79%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
4.71%
BV/share growth exceeding 1.5x Medical - Pharmaceuticals median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
-5.89%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
-0.94%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.